A detailed history of Us Bancorp \De\ transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 5,578 shares of ALNY stock, worth $1.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,578
Previous 7,094 21.37%
Holding current value
$1.33 Million
Previous $1.72 Million 10.97%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$233.81 - $287.01 $354,455 - $435,107
-1,516 Reduced 21.37%
5,578 $1.53 Million
Q2 2024

Aug 06, 2024

BUY
$143.31 - $247.0 $76,527 - $131,898
534 Added 8.14%
7,094 $1.72 Million
Q1 2024

May 07, 2024

SELL
$146.51 - $198.2 $101,238 - $136,956
-691 Reduced 9.53%
6,560 $980,000
Q4 2023

Feb 09, 2024

SELL
$151.41 - $196.57 $2,573 - $3,341
-17 Reduced 0.23%
7,251 $1.39 Million
Q3 2023

Nov 03, 2023

SELL
$170.77 - $211.65 $25,444 - $31,535
-149 Reduced 2.01%
7,268 $1.29 Million
Q2 2023

Aug 09, 2023

SELL
$185.01 - $212.05 $108,785 - $124,685
-588 Reduced 7.35%
7,417 $1.41 Million
Q1 2023

May 09, 2023

SELL
$182.66 - $235.53 $4,749 - $6,123
-26 Reduced 0.32%
8,005 $1.6 Million
Q4 2022

Feb 13, 2023

SELL
$185.53 - $241.31 $39,332 - $51,157
-212 Reduced 2.57%
8,031 $1.91 Million
Q3 2022

Oct 27, 2022

BUY
$138.54 - $232.0 $27,292 - $45,704
197 Added 2.45%
8,243 $1.65 Million
Q2 2022

Aug 01, 2022

SELL
$120.42 - $169.29 $268,777 - $377,855
-2,232 Reduced 21.72%
8,046 $1.17 Million
Q1 2022

May 11, 2022

BUY
$127.18 - $173.91 $86,355 - $118,084
679 Added 7.07%
10,278 $1.68 Million
Q4 2021

Feb 11, 2022

BUY
$159.56 - $209.29 $160,836 - $210,964
1,008 Added 11.73%
9,599 $1.63 Million
Q3 2021

Nov 10, 2021

BUY
$169.75 - $207.73 $18,333 - $22,434
108 Added 1.27%
8,591 $1.62 Million
Q2 2021

Aug 05, 2021

BUY
$128.63 - $176.89 $30,742 - $42,276
239 Added 2.9%
8,483 $1.44 Million
Q1 2021

Apr 28, 2021

BUY
$126.83 - $175.69 $784,570 - $1.09 Million
6,186 Added 300.58%
8,244 $1.16 Million
Q4 2020

Feb 04, 2021

BUY
$122.97 - $147.0 $101,327 - $121,128
824 Added 66.77%
2,058 $268,000
Q3 2020

Nov 10, 2020

BUY
$121.19 - $165.49 $14,421 - $19,693
119 Added 10.67%
1,234 $179,000
Q2 2020

Aug 07, 2020

BUY
$104.21 - $156.44 $7,398 - $11,107
71 Added 6.8%
1,115 $165,000
Q1 2020

May 13, 2020

SELL
$93.12 - $133.99 $11,174 - $16,078
-120 Reduced 10.31%
1,044 $114,000
Q4 2019

Feb 04, 2020

BUY
$74.51 - $124.23 $3,576 - $5,963
48 Added 4.3%
1,164 $133,000
Q3 2019

Nov 08, 2019

BUY
$70.9 - $87.82 $34,599 - $42,856
488 Added 77.71%
1,116 $89,000
Q2 2019

Aug 13, 2019

BUY
$65.86 - $92.79 $17,057 - $24,032
259 Added 70.19%
628 $46,000
Q1 2019

May 08, 2019

BUY
$72.76 - $93.45 $10,695 - $13,737
147 Added 66.22%
369 $35,000
Q4 2018

Feb 13, 2019

SELL
$62.67 - $88.33 $4,762 - $6,713
-76 Reduced 25.5%
222 $16,000
Q3 2018

Nov 01, 2018

BUY
$87.52 - $122.67 $12,427 - $17,419
142 Added 91.03%
298 $26,000
Q2 2018

Aug 08, 2018

SELL
$88.31 - $107.8 $18,810 - $22,961
-213 Reduced 57.72%
156 $15,000
Q1 2018

May 08, 2018

BUY
$115.92 - $148.54 $14,837 - $19,013
128 Added 53.11%
369 $45,000
Q4 2017

Feb 02, 2018

SELL
$114.49 - $139.98 $25,416 - $31,075
-222 Reduced 47.95%
241 $30,000
Q3 2017

Nov 13, 2017

BUY
$72.53 - $118.27 $33,581 - $54,759
463
463 $55,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $29.3B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Us Bancorp \De\ Portfolio

Follow Us Bancorp \De\ and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.